Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of AMG 416 in secondary hyperparathyroidism on hemodialysis
NL-OMON39880Phase 3Active, not recruiting
- Sponsor
- KAI Pharmaceuticals
- Start
- Nov 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of etelcalcetide, sponsored by KAI Pharmaceuticals. Started Nov 2013; status: active, not recruiting.
02
Drugs
etelcalcetide
Beyond the preview
Go deeper on NL-OMON39880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39880.